“We are so advanced at this because we leveraged
our unique global resources,” says CEO Chris Xu. His company, he says,
has a four-to-six month head start on other comparable shops in the U.S.
thanks to its collaboration with researchers in China.
He tells the Sacramento Bee that his company’s affordable treatment for coronavirus treatment could go to market within two months.
ThermoGenesis (NASDAQ:THMO) already has for sale a diagnostic kit for COVID-19.
https://seekingalpha.com/news/3563103-thermogenesis-hopes-for-coronavirus-treatment-sales-in-two-months
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.